AVAX Technologies' AC Vaccine™ improves relapse-free survival

-- Preclinical Data Presented at the 91st Annual Meeting of the American Association of Cancer Research --

Kansas City, MO, April 5, 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of preclinical data on its AC Vaccine™ technology, an autologous cell cancer vaccine, at the 91st Annual Meeting of the American Association for Cancer Research (AACR). The presentation outlined findings in a mouse model of breast cancer, indicating that vaccination with AVAX's AC Vaccine technology resulted in improved relapse-free survival. The dosage regimen used in the animal experiments is very similar to that currently being used in the company's pivotal registration trial of M-Vax™ for metastatic melanoma and in Phase 2 studies of O-Vax™ for ovarian cancer. This study was supported by a grant from AVAX and was conducted at the University of Illinois, Chicago, by Dr. Margalit B. Mokyr.

The study, entitled "Vaccination with DNP-Modified 410.4 Mammary Tumor Cells Leads to the Eradication of Established Metastases via a CD8+ T-Cell-Dependent Mechanism," was designed to assess the therapeutic potential of vaccination with irradiated tumor cells modified with the hapten "DNP" (AVAX's AC Vaccine technology), compared to treatment with tumor cells that were not modified via the AVAX process. The studies utilized a specific murine (mouse) mammary carcinoma, which closely models human breast cancer in terms of its immunogenicity, metastatic properties and growth characteristics. The data illustrated that treatment with DNP-modified irradiated tumor cells improved relapse-free survival of the mice, while treatment with unmodified cells had no effect. The study further indicated that vaccination with modified tumor cells elicited an immune response, which was identified by activation of CD8+ T-cells, and showed that these cells are a necessary component for the vaccine to achieve its effect in this model.

Contact: Olga Fleming
201-641-2408 ext. 51
AVAX Technologies, Inc.

Page: 1 2 3

Related biology news :

1. Palatin Technologies PT-141 increases sexual behavior in female animals
2. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
3. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
4. AVAX Technologies M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma
5. ASU researchers demonstrate new technique that improves the power of atomic force micrscopy
6. Study shows that ultrasound accreditation improves the quality of ultrasound practice
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Combination therapy dramatically improves function after spinal cord injury in rats
9. Moderate iron deficiency affects cognitive performance - but iron supplementation improves it
10. Longer-term, moderate exercise improves immune activity
11. New approach limits damage after heart attack and improves survival, say Scripps Research scientists

Post Your Comments:

(Date:6/19/2020)... ... June 18, 2020 , ... Join experts from Envigo ... in a live webinar on Wednesday, July 8, 2020 at 11am EDT ... we genetically engineer new models. However, while modifying the genome may be more straightforward, ...
(Date:6/11/2020)... ... June 09, 2020 , ... Superior Controls, Inc. ... automation and IT solutions for the life sciences industry, is pleased to announce the ... working out of the company’s Seabrook, New Hampshire office. In his new role, ...
(Date:6/5/2020)... ... ... Greffex, a pioneering vaccine and gene therapy company based in Houston, Texas, welcomes ... a global perspective to make an impact in a post pandemic world,” said Co-Chairman ... independent, director of the company. , “The Greffex board is excited to have Neil ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... , ... June 29, 2020 , ... ... to date growth of 40% in 2020, despite many obstacles created as a ... aims to increase revenue for its partnered medical practices and medical manufacturers by ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a leading provider of sensor ... of all types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ ... enabled business will provide a health performance index system that scores all aspects of ...
(Date:6/28/2020)... ... June 26, 2020 , ... The Security Industry ... its strong opposition to the recently introduced bicameral Facial Recognition and Biometric ... most federal use of nearly all biometric and related image analytics technologies, incorrectly ...
(Date:6/23/2020)... ... 2020 , ... Regen Suppliers, the one stop shop for ... get the fourth unit free with no limit on the amniotic derived exosomes. ... have been a game changer for regenerative therapies. The products are manufactured at ...
Breaking Biology Technology:
Cached News: